Hints and tips:
Related Topics
...Companies including Sandoz, Taro Pharmaceuticals, and Apotex have admitted their role in the conspiracies and paid penalties totalling almost $425m....
....; Ascend Laboratories, LLC; Apotex Corp.; Dr....
...Sanofi, the French pharmaceutical group, will receive a $270m payment from its generic rival Apotex over rights to its blockbuster blood thinner Plavix, briefly easing the impact of patent expiries on one...
...As part of the legal clean-up, GSK said it had resolved long-running antitrust litigation with Apotex, a rival drugmaker that introduced a generic version of Paxil, an antidepressant....
...He is also pursuing legal action against the FTC, which he claims illegally provided information to Apotex, a rival drug company, on Watson’s exclusive rights to launch a low-cost version of the drug Provigil...
...In the course of its probe, the FTC contacted both the Federal Drug Administration and a rival generic company, Apotex....
...“I would be very surprised to see Apotex winning at the end of April....
...Servier issued injunctions and reached out-of-court settlements with Krka and Lupin, and pursued legal action against Apotex....
...Apotex said it would appeal against the ruling....
...Chances are BMS will ultimately be able to defend the drug’s exclusive US rights against Apotex, the generic challenger. But Sanofi, as a party to the case, is in the best position to assess that....
...Anlalysts say they are increasingly likely to win on Plavix, but probably lost around $1bn in sales last year after Apotex, the generic challenger, flooded the market with its cheaper copy....
...The company said that supplies of a replica version of the drug made by Canadian group Apotex continued to cut into sales, but that the situation had improved from earlier in the year, when sales of Plavix...
...Bristol-Myers Squibb and Sanofi-Aventis’s troubled deal with Apotex highlights the tactics that traditional large pharmaceutical companies are being forced to adopt as they struggle to adjust to intensifying...
...The deal could be complicated by legal action in the US where BMS has been under investigation by the justice department since last summer over an agreement sought with Apotex, a generic manufacturer....
...The agreement calls for a damage rate, if applicable, at 40 to 50 per cent of Apotex’s generic Plavix sales....
...Wholesalers’ stockpiles of Apotex’s generic version are likely to last for several months yet....
...Investors do not know the full financial details of the deal with Apotex, but they presumably like the idea of knowing that Apotex would not enter the market until 2010 at the earliest, allowing them to...
...In their botched attempt to avoid Plavix litigation, the two struck a deal with Apotex....
...He was also optimistic of winning legal action against Apotex, the company which flooded the US market last year with its generic copy of the blood thinner Plavix, which Sanofi markets with BMS....
...Apotex says it can prove the patent is invalid....
...Under terms negotiated between Apotex, Bristol and Sanofi, Apotex was allowed a window to launch its version of Plavix before Bristol and Sanofi challenged the launch in court....
...The settlement provided Apotex with at least $40m....
...The investigation centres on a patent settlement Apotex, Bristol and Sanofi agreed in March that would have prohibited Apotex from launching a generic version of Plavix until 2011....
...The failed settlement with Apotex, a Canadian generic drugmaker, damaged the company’s profits and reputation just as Bristol appeared to be reviving its image after previous legal problems in Mr Dolan’s...
...The settlement provided Apotex with at least $40m – a provision that US regulators at the Federal Trade Commission questioned....
International Edition